In preclinical models of HER2 overexpressing tumors it has shown anti-tumor activity.[157] In phase I trials (NCT01097460, NCT01304784, NCT00911898), MM-111 was safe and well tolerated.[158] A phase II trial NCT01774851), however, did not show any benefit in combining MM-111 with paclitaxel plus trastuzumab in HER2 expressing gastroesophageal cancers (Table 6). Here, ERBB2 is linked to neoplasm.